About: Imalumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals. A phase I/II trial in patients with malignant ascites was terminated in 2016.

Property	Value
dbo:abstract	Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals. A phase I/II trial in patients with malignant ascites was terminated in 2016. (en)
dbo:casNumber	1430205-07-4
dbo:fdaUniiCode	22F97PC79G
dbo:wikiPageID	49239630 (xsd:integer)
dbo:wikiPageLength	3223 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	974019240 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Monoclonal_antibody dbc:Experimental_cancer_drugs dbr:Baxalta dbc:Monoclonal_antibodies_for_tumors dbr:Shire_Pharmaceuticals
dbp:casNumber	1430205 (xsd:integer)
dbp:legalStatus	Investigational (en)
dbp:synonyms	BAX69 (en)
dbp:type	mab (en)
dbp:unii	22 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies_for_tumors
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals. A phase I/II trial in patients with malignant ascites was terminated in 2016. (en)
rdfs:label	Imalumab (en)
owl:sameAs	yago-res:Imalumab wikidata:Imalumab https://global.dbpedia.org/id/2PNbT
prov:wasDerivedFrom	wikipedia-en:Imalumab?oldid=974019240&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Imalumab
is dbo:wikiPageWikiLink of	dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Imalumab